Welcome listeners to our fifth episode of our second season, that will delve into the complex realm of global clinical trials and the access Asian patients actually have had in novel/innovative treatments – quite probably one of the most inequitable of standards in healthcare and one that hasn’t been understood deeply enough. We’re a group of like-minded health editors, researchers and writers who’ve spent a career in trying to track the evolution of healthcare in parts of the developing world, particularly Asia-Pacific. So essentially this is a neutral, independent non-profit platform that aims to produce deep insights and knowledge on public health issues in Asia Pacific, rooted in local circumstances, experiences, and divergences.

We'll be joined today by two stalwarts of the oncology and clinical trial world, one who has represented th ...